An Oral Peptide Is Not Putting the Vial in a Capsule

Someone sells a “BPC capsule,” points at a vial photo, and the comments treat that gelcap like the same object that got an FDA label.

Here's the kindly fix. An oral peptide is not putting the vial in a capsule. Your search bar is mixing three different objects.

Think of three keys on one keyring: a labeled hotel key, a house key that looks similar but opens a different lock, and a spare blank you cut yourself. Same metal color. Completely different doors. Our house rule is Literature, not lore.

So what are the three objects?

Object one is an approved peptide tablet that needed an absorption enhancer — a helper that briefly helps a fragile chain slip through the stomach wall — and still lands near about one percent oral bioavailability (how much of the swallowed dose reaches the blood).

Object two is an approved GLP-1 pill that is not a peptide at all.

Object three is a research vial, or a gray-market capsule of the same nickname, whose “oral” story is mostly rodent drinking water — not a measured human absorption percent.

If you want the bead-string basics first, start with the live brief on what a peptide actually is.

Wait — can a real peptide even be a pill?

Yes. Rarely. And not by dumping powder into a gelcap.

Stomach acid and digestive enzymes are a woodchipper for most short protein chains. The peptide tablets that cleared FDA brought a helper. They did not ignore the woodchipper.

Oral semaglutide — the chain behind Rybelsus, the Wegovy pill, and the 2026 “Ozempic tablets” rename of one Rybelsus formulation — is co-formulated with SNAC (salcaprozate sodium). Absorption happens mostly in the stomach, local to the tablet. The label’s absolute bioavailability is still only about 0.4% to 1% on the older strengths, and about 1% to 2% on the higher-bioavailability ones. Those formulations are not milligram-for-milligram copies of each other. For the hormone lane, not a conversion chart, see the live brief on how GLP-1 changed metabolic research.

Lipfendra (enlicitide) is a mid-2026 example: a macrocyclic peptide PCSK9 inhibitor tablet with sodium caprate as the permeation enhancer. Label oral bioavailability is about 1%. Not a GLP-1. Not a research vial. Same lesson — chemistry help, tiny door.

A labeled peptide tablet is a VIP pass with a tiny door. A gelcap of vial powder is a different building.

Late-stage oral peptide programs also exist as trial tablets, not research vials, and not approved yet. For the broader map, see the live briefs Is the Future of Weight Loss Already Here? and Is the Next Weight-Loss Capsule Already Named?

Is every “GLP pill” a peptide?

No. That is object two — and you have probably seen the mix-up in a caption.

Orforglipron (Foundayo), in the live brief, is a once-daily oral small-molecule GLP-1 receptor agonist — a nonpeptide pill. Ordinary tablet excipients. Not a lyophilized chain. Not ILGLP-1, ILGLP-2, or ILGLP-3.

If your feed collapses “oral GLP” into “peptide capsule,” it just mixed object one with object two. Different chemistry. Different file.

What about BPC capsules, KPV pills, and the “Wolverine” nickname?

That is mostly object three — and a nickname is not a molecule.

BPC-157, as the live animal-literature brief lays out, has a large rodent literature, including papers that put it in drinking water. Reviews call it stable in gastric juice. Stability is not measured human oral bioavailability.

The systematic pharmacokinetics paper people should not misread — He et al., 2022 — dosed rats and dogs by vein and by muscle only. Half-life under half an hour. Intramuscular absolute bioavailability was roughly the teens in rats and the forties-to-fifties in dogs. There is no oral arm in that paper.

There is one registered human oral-tablet Phase 1 for BPC-157 (NCT02637284, PCO-02 / Bepecin). Status on ClinicalTrials.gov: UNKNOWN. No results posted. A protocol without a results table is a plan, not a percent.

KPV has real mouse oral literature — drinking water, a gut peptide transporter called PepT1 — and the live brief that KPV is not a compounding green light. That is still not a human tablet dossier.

“Wolverine” is gym slang for BPC-157 plus TB-500, not an INN and not a tablet. The live brief is clear that TB-500 is not the whole protein. A vial blend is still a vial blend — see the live GLOW and KLOW brief. Vendor capsules of those nicknames are not the labeled SNAC or sodium-caprate tablets above.

Did that July 2026 committee vote create oral drugs?

No. And if you saw a “FDA cleared” screenshot, that is the sticky-note problem again.

FDA’s Pharmacy Compounding Advisory Committee recommended BPC-157, TB-500, and KPV for the 503A Bulks List in July 2026, against FDA staff, by advisory votes (8–6 with one abstention on those three). Law-firm writeups of the meeting are clear: the vote is advice. It is not notice-and-comment listing. It is not drug approval. It is not a tablet specification.

Treating that sticky note like a stamped oral-drug license is exactly how object three gets sold as object one. Grade the gap the boring way — see the live brief on how this journal grades evidence.

The one thing to remember

An oral peptide is not putting the vial in a capsule. Approved peptide tablets needed an absorption trick and still land near about one percent. Some GLP pills are not peptides at all. Research vials and gray-market capsules of BPC, KPV, or a “Wolverine” nickname are a third file. Rodent oral stories and an unpublished tablet trial do not equal a labeled bioavailability percent.

Inspired Labs’ research catalog includes BPC-157 as a vial family for reading a lot (IL-COMP-BPC10 / IL-COMP-BPC5) — not an oral tablet SKU. Soft handoff here is lot identity plus a certificate of analysis, the live COA brief, not a gelcap rename. Neighbor vials of TB-500, a BPC/TB blend, and KPV follow the same rule. ILGLP-1 vials are not Rybelsus, not the Wegovy pill, and not Ozempic tablets.

For the fence around that language, see the live brief on what Research Use Only actually means. Research Use Only means laboratory research — not a shortcut that turns vial powder into a labeled tablet.